Compare Comcast Corporation (CMCSA) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Charles River Laboratories Intl. Inc — how do they compare? Comcast Corporation trades at $25.2 (market cap $91.02B), while Charles River Laboratories Intl. Inc trades at $285.81 (market cap $13.46B). The key difference: Comcast Corporation is far larger — about 6.8× Charles River Laboratories Intl. Inc's market cap, and Comcast Corporation pays a 5.15% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CMCSA | CRL | |
|---|---|---|
Market Cap | $91.02B | $13.46B |
Sector | Media | Health |
52-Week High | $32.50 | $282.00 |
52-Week Low | $21.92 | $145.57 |
Enterprise Value | $173.74B | $16.30B |
Dividend Yield | 5.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.20, down 0.63% today, with strong fundamentals including a P/E of 8.22 and net income margin of 8.97%. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI indicates potential overbought conditions. Recent earnings beats and a planned NBCUniversal spinoff provide positive catalysts, while analyst consensus remains strongly bullish with a $27.78 price target.
CMCSA presents compelling value with discounted valuation multiples and consistent cash flow generation. Key opportunities include wireless growth and media separation, while risks involve competitive pressures and potential economic headwinds affecting consumer spending. The stock offers a balanced risk-reward profile for long-term investors seeking stable returns.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
